TLR7 and ovarian carcinoma: Unresectable/metastatic solid tumours (including ovarian cancer).SHR2150 (TLR7 agonist) and chemotherapy plus anti-PD1 mAb or anti-CD47 mAb (specific mAb identities not provided).Non-randomised, open-label.